28 July 2020
Travis Perkins issue Trading update for six months to 30 June 2020…
A.G. BARR p.l.c., (“A.G. BARR” or the “Group”), which produces and markets some of the UK's leading drink brands, including IRN-BRU, Rubicon and Funkin, today announces a trading update in respect of the 26 weeks ended 25 July 2020….
Fresnillo Plc release interim results for the six months to 30 June 2020
…
27 July 2020
AstraZeneca's Calquence (acalabrutinib) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.1…
AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy….
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate…
Ahead of the Annual General Meeting to be held later today, the City Pub Group updates on trading for the three weeks since 4 July, when pubs were permitted to reopen in England following the easing of social distancing restrictions….
GlobalData Plc issue Unaudited Interim Report For The Six Months Ended 30 June 2020…